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The most characterized function of acetylcholinesterase (AChE) is to terminate
cholinergic signaling at neuron-neuron and neuro-muscular synapses. In addition, AChE
is causally or casually implicated in neuronal development, stress-response, cognition,
and neurodegenerative diseases. Given the importance of AChE, many studies have
focused on identifying the molecular mechanisms that govern its expression. Despite
these efforts, post-transcriptional control of AChE mRNA expression is still relatively
unclear. Here, we review the trans-acting factors and cis-acting elements that are known
to control AChE pre-mRNA splicing, mature mRNA stability and translation. Moreover,
since the Hu/ELAV family of RNA-binding proteins (RBPs) have emerged in recent years
as “master” post-transcriptional regulators, we discuss the possibility that predominantly
neuronal ELAVs (nELAVs) play multiple roles in regulating splicing, stability, localization,
and translation of AChE mRNA.
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INTRODUCTION
Acetylcholinesterase (AChE) is one of the most thoroughly stud-
ied enzymes andis better known for its role in hydrolyzing acetyl-
choline (ACh) at central and peripheral nervous system (CNS
and PNS)synapses (reviewed inLegay, 2000; Soreq and Seidman,
2001; Massoulie, 2002; Rotundo, 2003; Taylor, 2010). In addition
to terminating cholinergic neurotransmission, detection of AChE
prior to cholinergic synapse formation and in non-cholinergic
neurons led to identiﬁcation of functions in several cellular pro-
cesses including neurite elongation (Koenigsberger et al., 1997),
synaptogenesis (Sternfeld et al., 1998), cell adherence (Sharma
et al., 2001), and apoptosis (Zhang et al., 2002) (reviewed in Jiang
and Zhang, 2008; Paraoanu and Layer, 2008). The functional ver-
satility of AChE is also implicated in neocortical development
(Dori et al., 2005), cognition (Beeri et al., 1995), stress-response
(Kaufer et al., 1998), neuronal tumors (Karpel et al., 1994)a n d
neurodegeneration such as in Alzheimer’s and Parkinson’s dis-
eases (reviewed in Meshorer and Soreq, 2006; Greenﬁeld et al.,
2008).
AChE’s tissue-speciﬁc expression pattern and diverse roles
are largely attributed to the generation of multiple splice vari-
ants from a single gene (Li et al., 1991; Meshorer et al., 2004).
Classically, all AChE variants are categorized depending on their
different C-terminal tails into AChET (T-tailed), AChER (R-read
through) and AChEH (H-hydrophobic). In neurons and skele-
tal muscle AChET interacts with either a collagenic tail termed
ColQ, or with a proline-rich membrane anchor referred to as
PRiMA. On the other hand, AChEH is primarily localized to ery-
throcytes and platelets, anchored to the plasma membrane via
glycophospholipids. The typically low abundant variant found
in several cell types, AChER, is a soluble monomer up-regulated
during stress, AChE inhibition and organophosphate poisoning
(reviewed in Zimmerman and Soreq, 2006) .T h ei m p o r t a n c eo f
A C h Ef o rp r o p e rn e u r o n a ld e v e l o p m e n ta n ds y n a p t i cp h y s i o l -
ogy, as well as its putative roles in brain pathologies, has gathered
much attention over the last several decades toward delineating
the molecular mechanisms that control its expression.
Neuronaltranscription ofAChE hasﬁrst beenreported during
differentiation (Greene and Rukenstein, 1981,s e ea l s of o re x a m -
pleDeschenes-Furryetal.,2003),inresponsetostressors(Shapira
et al., 2000; Meshorer et al., 2004) and in co-cultures with
myotubes (Jiang et al., 2003). The murine AChE gene contains
ac o m p l e x5   regulatory region (5 RR) with alternate promoters
and two enhancers (Mutero et al., 1995; Atanasova et al., 1999;
Chanetal.,1999;Meshoreretal.,2004).Severaltranscriptionfac-
tors are now recognized to regulate AChE expression in neurons,
including activating transcription factor-1 (ATF1) (Wan et al.,
2000),glucocorticoidreceptors (GR)(Meshoreretal.,2004),hep-
atocyte nuclear factor 3β (HNF3β)( Shapira et al., 2000)a n d
ETS-like transcription factor (Elk-1) (Siow et al., 2010). At least
5 and 4 exon 1 (E1) variants have been identiﬁed in the mouse
(mE1a–e) and human (hE1a–d) AChE 5 RR, respectively, with
distinct promoters located upstream ofeach E1(Figure1A). Each
leader exon generates a unique AChE 5  untranslated region
(UTR), which is presumably dependent on alternative promoter
usage rather than alternative splicing. Although the purpose of
these various 5 UTRs remains elusive, mE1e and hE1d encode
a conserved (79%) amino acid chain that produces N-terminal
extended AChE variants (N-AChET,N - A C h E R and in principle
N-AChEH)( Meshorer et al., 2004). Interestingly, certain N-AChE
variants have been shown to bind the cellular membrane, pro-
mote apoptosis in stress-induced cells and to associate with
pathological markers in Alzheimer’s brains (Kehat et al., 2007;
Toiber et al., 2008, 2009).
In addition to transcription and distinct promote usage,
an increasing amount of studies are demonstrating that
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FIGURE 1 | Schematic diagrams depicting the mouse and human
AChE genes, alternative splicing options and cis-element locations.
(A) Mouse and human AChE genes, including the leader exons identiﬁed in
brain tissues. Noteworthy is the 5  regulatory region that harbors alternate
exons 1a–e in mouse and 1a–d in human (orange boxes), distal enhancer
glucocorticoid response element (brown line) and proximal muscle-speciﬁc
enhancer (pink line). Gray boxes and black lines represent constitutive
exons and introns, respectively. (B) Alternative splicing at the 3  end of
AChE pre-mRNA produces tissue-speciﬁc R (green), H (yellow) and T (blue)
variants. Approximate locations of the U-rich regulatory sequence, SC35
and ASF/SF2 splicing factor binding sites are denoted by black, white, and
gray stars, respectively. (C) The 3  untranslated regions (3 UTRs) of mature
T and R AChE variants and the alternative polyadenylation-dependent
extended regions. The AChEH variant is not shown since it is not
signiﬁcantly expressed in neurons. Symbols represent the PBE (black
triangle), ARE (gray triangle), miR-132 binding (white triangle), translation
stop (red octagon), and polyadenylation signal (p(A)) sites. 4  signiﬁes a
pseudo-intron that contains the AChER translation termination site.
Whether E6 and the downstream region are included in AChER transcripts
is unknown (?).
post-transcriptional mechanisms are equallyimportant for AChE
expression. However, our understanding of the trans-acting fac-
tors and cis-acting elements involved in these processes is still
limited. Here, we review the work describing the currently identi-
ﬁed RNA-binding proteins (RBPs), microRNAs (miRs) and RNA
motifs that regulate AChE pre-mRNA splicing, mRNA stability,
andtranslation.Giventheestablished neuronalpleiotropiceffects
of one family of RBP, namely the principally neuronal ELAVs
(nELAVs),wealsospeculateontheirinvolvementinAChEmRNA
metabolism at multiple steps.
REGULATION OF AChE PRE-mRNA SPLICING
Recent high throughput sequencing revealed that more than
90% of human genes undergo alternative splicing (for review
see Kalsotra and Cooper, 2011). In accordance with this ﬁnd-
ing, AChE pre-mRNA is subjected to alternative splicing at the
3 end, which produces AChET or AChER in neurons. The ter-
minal sequence of the AChE gene contains a 5  splice donor
site downstream of exon 4 (E4) and two 3  splice acceptor sites,
one upstream of E5 (proximal) and the other upstream of E6
(distal). When splicing to either of the two downstream accep-
tor sites is inhibited, the intron (4 ) and exons downstream of
E4, are included into the mature transcript producing AChER.
Conversely, splicingtothedistalacceptorsiteincorporatesE6into
the mature mRNA and generates AChET (reviewed in Meshorer
and Soreq, 2006)( Figure1B).
Although little is known regarding the splicing factors
involved, two serine/arginine-rich (SR) auxiliary splicing fac-
tors, SC35 and ASF/SF2, have been found to inversely affect
AChER versus AChET expression (Meshorer et al., 2005). In
particular, in vitro experiments with an AChE minigene in COS-
1 and HEK293 cells unveiled that SC35 promotes alternative
splicing of AChER transcripts whereas ASF/SF2seemed to favor
expression of AChET. Furthermore, immunohistochemistry and
ﬂuorescent in situ hybridization (FISH) experiments detected a
correlation between SC35 protein and AChER mRNA expression
during embryonic brain development and adult stress-response.
However, some discordance between SC35 protein and AChER
mRNA levels in developing and post-stress cortex were apparent
(Meshorer et al., 2005), indicating that other trans-acting factors
may also govern splicing of precursor AChE mRNAs. In agree-
ment with this view, Guerra et al used an AChE minigene and
sequence mutagenesis to uncover various putative motifs, pre-
dominantly located in the E5 non-coding region, that inﬂuence
production of the R/H/T splice variants in skeletal muscle cells
(Guerra et al., 2008).
STABILITY-DETERMINANTS OF AChE mRNA
Post-transcriptional regulation of AChE resulting in increased
mRNA stability was initially documented in Neuro2a (N2a)
cells under the control of the thyroid hormone T3 (Puymirat
et al., 1995) and in differentiating P19 embryonal carcinoma
cells (Coleman and Taylor, 1996). Moreover, increased stabil-
ity of AChE mRNA through an unknown mechanism has been
observed during calcium-dependent apoptosis (Zhu et al., 2007).
Screening the AChET transcript sequence for cis-acting elements
that might regulate mRNA stability revealed the presence of an
AU-rich element (ARE) in the 3 UTR and a CU-rich sequence in
E2 (Cuadrado et al., 2003; Deschenes-Furry et al., 2003). Based
on the current understanding of AChE alternative splicing, it
would appear that the R transcript also contains these motifs.
However,whether the ARE-surroundingsequencethatisencoded
by E6 is also present in AChER remains controversial (Guerra
et al., 2008; Camp et al., 2010; Hanin and Soreq, 2011; Marrero
et al., 2011)( Figure1C). In either case, the existence of an ARE
indicates RBP-dependent regulation of AChE mRNA stability.
AChE transcripts are also susceptible to alternative polyadeny-
lation that preferentially produces a shorter 3 UTR in mature
neurons with an expected altered mRNA stability (Figure1C)
(Li et al., 1991).
One of the most extensively studied families of mRNA stabi-
lizing RBPs, termed the Hu/ELAV family, consists of the ubiqui-
tously expressed HuR (ELAVl1) and the predominantly neuronal
(known as nELAVs) HuB (ELAVl2), HuC (ELAVl3) and HuD
(ELAVl4) (reviewed in Bolognani and Perrone-Bizzozero, 2008;
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Hinman andLou,2008;Pascaleetal.,2008).Braindevelopmental
andspatialexpressionpatternsofHu/ELAVmembersarepartially
distinct andtheir amino acid sequences aremoderately conserved
in certain regulatory regions, suggesting that these RBPs are not
completely functionally redundant (Okano and Darnell, 1997;
Hambardzumyan et al., 2009). Hu/ELAVs contain two RNA-
Recognition Motifs (RRMs) which enable binding to AREs in
the 3 UTR and a third RRM that interacts with the poly(A)-tail
and other proteins (Abe et al., 1996; Ma et al., 1997; Kasashima
et al., 2002; Fialcowitz-White et al., 2007). Recent studies indi-
cate that both ARE and non-ARE sequences located in 5 UTRs,
exons and introns are also targeted by Hu/ELAVs (Bolognani
et al., 2010; Lebedeva et al., 2011; Mukherjee et al., 2011; Uren
et al., 2011). Through these binding mechanisms, Hu/ELAVs can
regulate almost all aspects of mRNA metabolism including splic-
ing, polyadenylation, nuclear export, stabilization, localization,
and translation (reviewed in Hinman and Lou, 2008; Pascale
et al., 2008—and see below). Since several nELAV mRNA targets
encode proteins thathaveessential roles rangingfromneurogene-
sistosynaptogenesis, nELAVsactas“master”post-transcriptional
regulators of neuronal development, maintenance, and function
(Bolognani et al., 2010 and for review see Deschenes-Furry et al.,
2006; Pascale and Govoni, 2012).
The lack of positive correlation between transcription rate and
AChE mRNA levels (see for example Boudreau-Lariviere et al.,
2000; Angus et al., 2001) together with the presence of an ARE
motif in the AChE transcript prompted us several years ago, to
initiate a series of studies to determine whether nELAVs control
AChE mRNA stability. Using several complementary approaches,
we were able to show that HuD binds to the ARE-containing
region in the 3 UTR and enhances AChE mRNA abundance fol-
lowing its ectopic expression in PC12 cells (Deschenes-Furry
et al., 2003). Around the same time, the group of Cuadrado et al
used an in vitro RNAse protection assay to establish that HuD
binds to the AChE ARE and CU-rich sequence. In a congruent
experiment to ours, they were able to demonstrate that overex-
pression of HuD is sufﬁcient to increase AChE mRNA expression
in N2a cells (Cuadrado et al., 2003). Moreover, similar ﬁndings
were obtained in a skeletal muscle differentiation model when we
demonstrated that HuR also binds to the AChE 3 UTR thereby
stabilizing the transcript (Deschenes-Furry et al., 2005).
In subsequent work, we ascertained that the regulation of
AChE mRNA stability by HuD also occurs in vivo.T ot h i se n d ,
we conducted experiments using two distinct models. First, we
made use of transgenic mice overexpressing HuD in regions
of the brain. In these animals, we detected through in situ
hybridization and RT-PCR experiments, an increase in AChE lev-
els in brain regions showing high levels of transgene expression.
Furthermore, RNA immunoprecipitation experiments conﬁrmed
in vivo an interaction between the HuD transgene product and
endogenous AChE transcripts. In a second approach, axotomy of
neurons of the spinal cervical ganglion (SCG) produced a con-
comitantdecreaseinAChEmRNAandHuDproteinlevels,aswell
as a clear reduction in their interaction. Importantly, the decrease
in AChE mRNA abundance could be rescued by localized over-
expression of HuD delivered via a viral vector (Deschenes-Furry
et al., 2007). Together, these in vitro and in vivo studies high-
light the critical importance of HuD in controlling AChE mRNA
stability (Figure2) during neuronal development and following
injury. Whether these functions extend to the other nELAVsisnot
presently known.
LOCALIZATION AND TRANSLATION OF AChE TRANSCRIPTS
Transport of mRNAs into neurites necessitates a heterogeneous
and dynamic assembly of proteins, known as ribonucleopro-
tein (RNPs) particles, onto 3 UTR cis-elements (Figure2). RNP
AChE mRNA
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FIGURE 2 | A model illustrating post-transcriptional regulation of
AChE expression and localization in neurons by trans-acting
factors. (A) Alternative splicing of AChE pre-mRNA is controlled by SC35
and ASF/SF2 general splicing factors. As part of a ribonucleoprotein particle
(RNP), nELAVs might also bind to cis-elements within the AChE
pre-mRNA to regulate alternative splicing. (B) AChE mRNA is stabilized
by HuD and possibly other nELAVs. Stabilization of AChE mRNA could
depend on nELAVs outcompeting destabilizing RBPs and/or RISC
loaded miR-132, thereby preventing exosome-mediated mRNA
degradation. (C) RNPs, conceivably containing nELAVs and Pumilio 2
(Pum2), transport translationally repressed AChE transcripts along
microtubules into neurites. (D) At the synaptic terminal, AChE
translation might be promoted by nELAVs or inhibited by Pum2 or RISC
loaded miR-132.
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components stabilize the transcript, inhibit translation during
transport and promote/repress protein synthesis at the synapse
(reviewed in Wang et al., 2010a; Liu-Yesucevitz et al., 2011).
In a potentially analogous mechanism, translocation of AChER
m R N A si n t on e u r i t e sc o r r e l a t e sw i t hi n c r e a s e dA C h Ea c t i v i t yf o l -
lowing physiological stress, AChE inhibition or corticosterone
treatment (Meshorer et al., 2002). Collectively with the discov-
ery of augmented AChER transcript levels in cortical neurites
subsequent to AChE inhibition (Kaufer et al., 1998), these ﬁnd-
ings support the notion that post-transcriptional events regulate
AChER mRNA translocation and possibly local translation at the
neurite terminal (Meshorer and Soreq, 2006).
In agreement with this view, a study by Marrero et al has
recently identiﬁed Pumilio2(Pum2)asaregulator ofAChE trans-
lation(Marreroetal.,2011). Pum2isamember ofthe PUFfamily
of RBPs that bind to distinct Pumilio binding elements (PBEs)
in 3 UTRs of mRNAs and inhibit their translation (reviewed in
Quenault et al., 2011). Using protein-RNA binding assays, the
authors demonstrated that Pum2 speciﬁcally binds to a PBE ele-
ment in the 3 UTR and consequently represses AChE translation
(Marrero et al., 2011). Although these studies were conducted in
skeletal muscle, Pum2 is also found in the nervous system, where
it controls synaptic function and dendrite outgrowth (Vessey
et al.,2010). Furthermore, disruptionofPum2 impairs long-term
memory in Drosophila while its ablation produces numerous
behavioural defects in mice (Dubnau et al., 2003; Siemen et al.,
2011). Together, these studies suggest that Pum2 may inhibit
AChE translation during transport and at synaptic termini in
neurons (Figure2).
MicroRNA REGULATION OF AChE EXPRESSION
Stability and translation of mRNAs are also under the inﬂuence
of miRs, which are short (∼23 nt) single-stranded non-coding
RNAs. MiRs function by imperfectly binding to target sequences,
usually in the 3 UTR, thereby promoting transcript degradation
and/or translational silencing when loaded into the miR-induced
silencing complex (miRISC) (Berezikov, 2011). Recently, Shaked
et al. used a reporter assayalong with binding site point mutation
in cultured CHO cells to demonstrate that miR-132 targets the
AChE 3 UTR. The authors then elaborated on these ﬁndings in
vivo by showing that miR-132 overexpression and locked nucleic
acid (LNA)-mediated reduction decreased and increased, respec-
tively, AChE catalytic activity in bone marrow cells (Shaked et al.,
2009).
MiR-132 is also abundant in the brain implying that AChE
is subjected to this regulatory event in neurons (Cheng et al.,
2007). Indeed, a very recent study revealed that transgenic mice
overexpressing AChER transcripts lacking the 3 UTR contain
elevated miR-132 levels which correlate with decreased AChET
mRNA abundance in the hippocampus (Shaltiel et al., 2012).
However, it remains to be tested whether miR-132 induces AChE
mRNA translational inhibition, degradation or both (Figure2).
Additional bioinformatics analysis of 3 UTR sequences further
identiﬁed at least 47 and 81 putative miR sites in AChET and
AChER, respectively (Hanin and Soreq, 2011); though the func-
tionality of these sites requires validation. Amongst these poten-
tial sites, at least 13 miRs, for example miR-124, -125b, -194
and-214,areofgreater interestbecausetheyhavebeenimplicated
in neuronal development, regeneration, and/or brain diseases
(Saba and Schratt, 2010; Hanin and Soreq, 2011).
IMPLICATION OF Hu/ELAVs IN REGULATING AChE mRNA
METABOLISM AT MULTIPLE STEPS
It is now well established that members of the Hu/ELAV family of
RBP can exert multiple effects on RNA metabolism by assuming
several distinct, yet complementary functions. Thus, the multi-
functional nature of Hu/ELAVs in controlling the fate of mRNAs
suggests that these RBPs regulate more than stability of AChE
transcripts. In support of this idea, a recent compilation of high
throughput data implicates HuR in coupling pre-mRNA alterna-
tive splicing to mRNA stability. More speciﬁcally, nascent HuR
targets that contain both intronic and 3 UTR binding sites were
f o u n dt ob em o r es t a b l et h a nt h o s et h a td on o t( Mukherjee et al.,
2011).
In view of this, a U-rich sequence in the AChE E5 non-
coding region was demonstrated to control splicing to the distal
3  splice site to favorAChET expression in skeletal muscle(Guerra
et al., 2008). Interestingly, the Hu/ELAV family has been shown
to control pre-mRNA splicing by binding to AU- and U-rich
sequences (reviewed in Hinman and Lou, 2008). For example,
one study demonstrated that nELAVs regulate splicing of the cal-
citonin/calcitonin gene-related peptide (CGRP) pre-mRNA in a
neuron-speciﬁc manner by outcompeting TIA/TIAR splicing fac-
tors for U-rich intronic binding sites (Zhu et al., 2006). Various
Hu/ELAV members were shown to similarly bind and control
splicing ofFas(Izquierdo,2010), Neuroﬁbromatosistype1 (NF1)
(Zhu etal.,2008), Ikaros(Bellavia et al.,2007)an dev e nH uDpr e -
mRNAs (Wang et al., 2010b). In most of these cases Hu/ELAVs
were found to function as splicing repressors with the only excep-
tion being a splicing enhancement role on HuD pre-mRNA
(Wangetal.,2010b).Basedontheirestablishednuclearfunctions,
nELAVs could thus regulate splicing of AChE 3  alternative exons
by competing for the U-rich site within the E5 non-coding region
(Figures 1B and 2).
In addition to governing pre-mRNA splicing, compelling evi-
dence supports a role for nELAVs in regulating both localization
and translation of ARE-bearing transcripts in neurites (reviewed
in Pascale et al., 2008). For instance, two ARE-containing HuD
target mRNAs that are both involved in axon outgrowth namely,
GAP-43 and Tau, colocalize with HuD protein and polysomes in
growth cones during neuronal differentiation (Smith et al., 2004;
Atlas et al., 2007). Co-immunoprecipitation and in vitro binding
assays revealed that HuD interacts with a motor protein, KIF3A,
and directly binds to a microtubulecomponent, MAP1B (Aronov
et al., 2002; Fujiwara et al., 2011). Strengthening the notion of
nELAV-mediated translation, HuD was shown to enhance cap-
dependent protein synthesis and PC12 cell neurite extension by
binding to eIF4A and the poly(A)-tail of transcripts (Fukao et al.,
2009). Hu/ELAV members are also capable of repressing transla-
tion through a mechanism that is unclear but appears to depend
on the target transcript and/or the cellular context (Kullmann
et al., 2002; Meng et al., 2005). Based on these ﬁndings, it is con-
ceivable that nELAVs regulate both AChE mRNA stability and
translation in neurons, in a manner analogous to that previously
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observed for the mRNA targets GLUT1 and NOVA-1 (Jain et al.,
1997; Ratti et al., 2008).
CONCLUDING REMARKS
Despite extensive research into the regulation of AChE expres-
sion, only a handful of studies have precisely described some of
the molecular mechanisms that control AChE expression, partic-
ularly at the post-transcriptional level. Currently, our knowledge
of trans-acting factors and cis-acting elements that affect AChE
pre-mRNA splicing,maturemRNAstability, transportandtrans-
lation is rather limited. Nevertheless, some progress has been
made over the years and increasing evidence suggests that RBPs
(SC35,ASF/SF2,HuDandPum2)andatleastonemiR(miR-132)
play integral roles in controlling AChE expression in cholin-
ergic and non-cholinergic neurons under various physiological
contexts (see above). Based on their implications in neurogen-
esis and synaptic plasticity, trans-acting factors may also regu-
late AChE expression during learning and memory (Quattrone
et al., 2001; Mellios et al., 2011; Siemen et al., 2011; Tognini
et al., 2011; Apostolatos et al., 2012). Under such circumstances,
post-transcriptional events might differentially regulate AChET
versus AChER at multiple levels, since the expression patterns
and functions of these variants are often contrasting (reviewed
in Meshorer and Soreq, 2006). Control of mRNA stability, trans-
port and local translation would facilitate temporal and spatial
expression ofAChE variantsatgrowthconesandmaturesynapses
and thus contribute to the multifaceted biochemical, morpholog-
ical and physiological modiﬁcations necessary for neuronal dif-
ferentiation, synaptic plasticity and stress-response. Conversely,
altered abundance and/or function of trans-acting factors, such
as nELAVs and consequently AChE, may be directly or indirectly
involved in neurodegenerative pathogenesis, namely Alzheimer’s
disease (Berson et al., 2008; Amadio et al., 2009). In light of
the emerging role of post-transcriptional events governing AChE
metabolism, it is now clear that a thorough knowledge of all
mechanisms controlling AChE expression andlocalization is nec-
essary if the ultimate goal is to better understand neuronal devel-
opment and function including neurogenesis, stress-response,
cognition, neurodegeneration, as well as other brain diseases and
injuries.
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